Bristol-Myers Squibb / Sanofi-Synthelabo Partnership
Bristol-Myers Squibb Company, often referred to as BMS, and Sanofi-Synthelabo, a subsidiary of Sanofi, have established a strategic partnership that enhances their capabilities in the biopharmaceutical industry. Headquartered in Denmark, this collaboration focuses on innovative therapies across oncology, immunology, and cardiovascular health, aiming to address unmet medical needs globally. Founded in the early 19th century, both companies have achieved significant milestones, including groundbreaking advancements in drug development. Their core products, such as immunotherapies and biologics, are distinguished by their unique mechanisms of action and efficacy. This partnership not only strengthens their market position but also underscores their commitment to improving patient outcomes through cutting-edge research and development.
DitchCarbon Score
How does Bristol-Myers Squibb / Sanofi-Synthelabo Partnership's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol-Myers Squibb / Sanofi-Synthelabo Partnership's score of 47 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol-Myers Squibb / Sanofi-Synthelabo Partnership's reported carbon emissions
Bristol-Myers Squibb and Sanofi-Synthelabo, headquartered in Denmark (DK), currently do not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that both companies are likely engaged in various climate commitments and initiatives aimed at reducing their environmental impact. However, specific reduction targets or achievements have not been disclosed. The pharmaceutical industry is increasingly focusing on sustainability and carbon neutrality, and it is expected that Bristol-Myers Squibb and Sanofi-Synthelabo are aligning their strategies with industry standards. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate pledges, although no specific targets have been mentioned in the available information. Overall, while concrete emissions data and reduction targets are not currently available, the companies are expected to be actively working towards enhancing their sustainability practices in line with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb / Sanofi-Synthelabo Partnership is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
